UBC Services Support Increasing Demands of Specialty Market

UBC Services Support Increasing Demands of Specialty Market

Less than one percent of the U.S. population uses specialty therapies, yet specialty drugs receive significant resources and development from pharma manufacturers.  Last year marked the third consecutive year specialty drugs made up the majority of drugs approved by the FDA. 

The number of drugs approved in 2012 was the highest since 1996.  And, 2013 could also see 30+ drug approvals.  Of the 37 medications approved in 2012, 10 are for the treatment of cancer, and 10 are orphan drugs

Supporting the market’s growing demand for specialty therapies is going to require a fresh approach.  Safety, loyalty, and access services must evolve in unison with changing market dynamics, and manufacturers will benefit from resources anchored with specialty experience.

Working hand-in-hand with Express Scripts’ specialty pharmacy and specialty distribution organizations, Accredo and CuraScript, UBC is uniquely positioned to seamlessly integrate best-in-class services for specialty therapies throughout their lifecycle.  From clinical development to supply chain management, manufacturers are counting on the experience, knowledge, and diverse service suite a provider with deep specialty roots can offer.